Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 44.79M P/E - EPS this Y 35.10% Ern Qtrly Grth -
Income -37.34M Forward P/E -1.58 EPS next Y 2.30% 50D Avg Chg -5.00%
Sales - PEG - EPS past 5Y - 200D Avg Chg -30.00%
Dividend N/A Price/Book 3.40 EPS next 5Y - 52W High Chg -72.00%
Recommedations 1.70 Quick Ratio 0.18 Shares Outstanding 56.27M 52W Low Chg 35.00%
Insider Own 0.50% ROA -174.27% Shares Float 55.63M Beta 2.37
Inst Own 10.45% ROE - Shares Shorted/Prior 5.27M/4.51M Price 1.58
Gross Margin - Profit Margin - Avg. Volume 154,591 Target Price 6.83
Oper. Margin - Earnings Date May 9 Volume 138,762 Change -3.66%
About SELLAS Life Sciences Group, Inc

SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.

SELLAS Life Sciences Group, Inc News
03/28/24 SELLAS Life Sciences Reports Full Year 2023 Financial Results and Provides Corporate Update
03/26/24 SELLAS Announces Positive Topline Data from the Phase 2a Study of SLS009 in r/r AML and Provides Steering Committee Update on Phase 3 REGAL Study
03/19/24 SELLAS Life Sciences Group Announces Closing of $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
03/19/24 SELLAS Life Sciences to Host Corporate Update Call on March 26, 2024, at 8:15 am ET
03/15/24 SELLAS Life Sciences Group Announces $20 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules
03/08/24 SELLAS Announces Executive Leadership Reorganization and Prioritization of Commercialization Partnerships
03/01/24 SELLAS Life Sciences Delivers Oral Presentation of SLS009 Phase 1 Data for Acute Myeloid Leukemia Patients at 2024 European School of Haematology (ESH) Conference
02/29/24 SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference: Updated Date and Time
02/06/24 SELLAS Announces Publication of Preclinical Data on its Highly Selective CDK9 Inhibitor, SLS009, in Oncotarget
01/25/24 SELLAS Life Sciences to Present SLS009 Phase 1 Data from Acute Myeloid Leukemia Patients at the 2024 European School of Haematology (ESH) Conference
01/10/24 SELLAS (SLS) Rises on FDA Fast Track Tag to Leukemia Candidate
01/09/24 SELLAS Life Sciences Receives FDA Fast Track Designation for SLS009 for Treatment of Relapsed/Refractory Acute Myeloid Leukemia and Provides Updated Data for Phase 2a Study of SLS009 in Relapsed/Refractory Acute Myeloid Leukemia Patients
01/04/24 SELLAS Life Sciences Announces Pricing of $9.0 Million Public Offering
01/03/24 SELLAS Life Sciences Announces Proposed Public Offering
01/03/24 SELLAS Provides Corporate Updates and Highlights Key Upcoming Milestones
12/27/23 SELLAS Life Sciences Reports Positive Follow-Up Immune Response and Survival Data in Completed Phase 1 Study of Galinpepimut-S Combined with Opdivo® in Advanced Malignant Pleural Mesothelioma
12/21/23 SELLAS Receives FDA Orphan Drug Designation for SLS009 for Treatment of Peripheral T-cell Lymphomas
12/14/23 SELLAS Life Sciences Announces First Patients Enrolled in 60 mg Dose Cohort in Phase 2a Clinical Trial of SLS009 in Acute Myeloid Leukemia
12/13/23 SELLAS to Host Corporate Update Webinar on January 3, 2024 at 8:30 am ET
12/04/23 SELLAS Life Sciences Announces Positive Recommendation from REGAL Independent Data Monitoring Committee of Galinpepimut-S in Acute Myeloid Leukemia
SLS Chatroom

User Image Bless_immuno Posted - 4 minutes ago

$SLS It's like they've got us in a headlock, squeezing just enough to make us cough up those last shares! With the trading volume drying up, they're left with no choice but to push the prices higher, hoping we'll throw in the towel and hand over our precious shares.

User Image FatherofTrades Posted - 8 minutes ago

$SLS $HUMA $ICU Todays day trade is $PRSO, called at 1.70. Use tight SLs and scale out.

User Image HeloGuy89 Posted - 12 minutes ago

$SLS With the quiet period in effect before Thursday night's ER release, I suspect that our awaited imminent news will have to wait until Friday at the earliest. I suspect price action won't do much until after then.

User Image canecoleman Posted - 13 minutes ago

$SLS 35,000 vol in premarket + first 10 mins trading… What are these MMs doing😂😂😂

User Image HeavyBagHolder69 Posted - 16 minutes ago

$SLS all these pumpers and they can’t buy more than 10k shares this morning?

User Image canecoleman Posted - 20 minutes ago

$SLS alright volume has fully dried up… Less than 3k vol opening candle. Longs are all locked in and happy to wait patiently😂😅 75 million markecap for interim analysis imminent of phase 3… thats laughable. Happy to hold and add patiently

User Image cb5000calls Posted - 24 minutes ago

$SLS exactly! RSI on the monthly has this higher than the last run to $19... so much illegal manipulation to continue holding the price at this level.

User Image nonstoptrades Posted - 29 minutes ago

$JAGX news is awesome. Reduces the need for feeding tube for chemo patients and FDA approval with commercialization plan. Love it. Now we need some action on $SLS next week.

User Image GoEagles1 Posted - 43 minutes ago

$SLS Got a tip on this stock following FatherofTrades. I've made nearly $1000 profit on day and swing trades in less than 6 trading days with him. Real deal and free.

User Image cb5000calls Posted - 52 minutes ago

$SLS last chart was showing bull flag on the 1 hour. Look at the weekly. Megaphone bottom with a measured target at $3.10-$3.50, that's just the start. Weekly MACD has just crossed over the baseline. First time since 2/10/2023. RSI looking stronger than ever. Every bullish technical indicator is triggering. POS MM needs to stop holding this down and let it not only close all the massive daily gaps to the upside but also the weekly gap sitting at $4.13-$4.377. Beyond ready for a $CADL $HOLO $TPST type of launch.

User Image cb5000calls Posted - 57 minutes ago

$SLS ever seen a bull flag.... Time for this to launch and return to a realistic market cap filling all the daily gaps to the upside that shorts have manipulated with over the last 3+ years. $1.49-$1.52 $1.92-$3.659 $4.13-$4.50 $5.58-$6.68 $8.50-$8.71 $25.86-$26 $38.50-$39 Phase 3 Regal Steering Committee Interim IMMINENT! $XBI $SPY $QQQ

User Image Rednovember24 Posted - 1 hour ago

@FatherofTrades standing by! Gives me something productive to do other than checking the $SLS board every 5 minutes…

User Image FatherofTrades Posted - 1 hour ago

$SLS real shit. No rocket emojis. Money talks. I’ve been funneling my day trade profits into this and my other 2 favorites. GLTA! DYODD! MAKE THE MONEY!

User Image godloveyou Posted - 1 hour ago

$SLS Take the train to the moon. There aren't many seats left in the front row~~

User Image cea Posted - 1 hour ago

@Abone1991 Alex, one other thing. Unfortunately, we have some bad actors on the $SLS board…on both sides of the trade. We have some that preach $SLS is a scam and others that preach $SLS is going to solve cancer and make us all billionaires; the truth is somewhere in between. Most of us are very hopeful and will be helpful in your DD, but you have to do your share. As always, invest only what you can afford to lose; if you attempt to day trade on $SLS you could lose your shirt.

User Image FatherofTrades Posted - 1 hour ago

As requested, I’ll be posting another day trade shortly after market opens. I’m glad you’ve all been enjoying them and making money. PLEASE remember to use a tight SL where you’re comfortable. I am eyeing a few tickers, but need to see market open first. $ICU $SLS $HUMA long and strong. These day trades are just games and profit while we wait on our favorites.

User Image jonnyloitering Posted - 1 hour ago

$SLS “The stock market is a device to transfer money from the impatient to the patient.”

User Image MrBlockchain Posted - 1 hour ago

$SLS What be happnin in SLSville? Are we all dead r what? More exciting repertoire will keep us entertained as we wait. In the end, it'll be another day behind us.

User Image Lucy2022 Posted - 1 hour ago

$SLS

User Image Rdanser Posted - 1 hour ago

$SLS

User Image bhmin098 Posted - 1 hour ago

$SLS Bullish! Definitely!

User Image AVAVAV Posted - 2 hours ago

$SLS

User Image OnTheBalance Posted - 2 hours ago

$SLS Some thoughts for shareholders. Remain dignified. No giphys and to-the-moon stuff. And if you really want to stiff the shorts, buy a few more shares. That’s my plan for next few days.

User Image Bullrunners Posted - 2 hours ago

$SLS

User Image anthonyjacobs Posted - 3 hours ago

$SLS Good news is already priced in.

User Image PrettyGuyEyesNThighs Posted - 3 hours ago

$SLS I feel like we have gained thousands of followers over the past couple weeks! Claps y’all let’s drive this to the moon, I believe!

User Image DD_patience Posted - 3 hours ago

$SLS No run up means even more violent move up… this is 10+ easy within 2 weeks!!

User Image godloveyou Posted - 4 hours ago

$SLS Sometimes you just have to enjoy the waiting~~

User Image DD_patience Posted - 4 hours ago

$SLS

User Image Marcus737 Posted - 5 hours ago

$SLS Are they now talking to the fda about breakthrough therapy designation sls009 , or june?

Analyst Ratings
Cantor Fitzgerald Overweight Nov 22, 23
Cantor Fitzgerald Overweight Sep 7, 23
Alliance Global Partners Buy Nov 15, 22
Cantor Fitzgerald Overweight Jun 28, 22
Cantor Fitzgerald Overweight Jul 21, 21
Maxim Group Buy Nov 15, 19
Alliance Global Partners Buy Apr 8, 19
Oppenheimer Outperform Nov 1, 18
Maxim Group Buy Jul 20, 18